Quick answer
In a 2021 trial with 28 patients with diabetic foot ulcers, wounds treated with placenta-derived mesenchymal stem cells shrank 66%, versus 36% with standard care. A 2025 meta-analysis of six trials found a higher chance of complete closure with cell therapies. The evidence is promising but still limited.
Why it matters
Diabetic foot ulcers are slow to heal and can lead to infection and amputation. Mesenchymal stem cells release signals that support new blood vessel formation and tissue repair.
What the studies found
- 28 patients (2021): wound area decreased 66% with stem cells versus 36% with standard care.
- Meta-analysis of 6 trials (2025): a higher chance of complete closure (relative risk 1.63).
What it means for you
A complement to specialized wound care, never a replacement. In Veracruz, Longevity Clinic works with Centrie, a clinical foot centre, on these cases.
Studies cited
Meamar R, et al. International Immunopharmacology
Improved wound healing of diabetic foot ulcers using human placenta-derived mesenchymal stem cells in gelatin electrospun nanofibrous scaffolds plus a platelet-rich plasma gel: A randomized clinical trial
Reported result: Wound area decreased 66% with stem cells, 71% with stem cells plus platelet-rich plasma and 36% with standard care. The authors observed new blood vessel formation in treated tissue.
Mei XH, et al. International Journal of Lower Extremity Wounds
Efficacy of Mesenchymal Stem Cells in the Treatment of Diabetic Foot Ulcers: A Meta-Analysis of Randomized Controlled Trials
Reported result: Higher probability of complete ulcer closure with mesenchymal stem cells than with control: relative risk 1.63 (95% CI 1.23–2.16).